Rituximab

Where the papers sit

27 papers from the last 6 months study rituximab directly · updated from PubMed 10 Oct 2026

• Cross-Disease B-Cell Therapy

  Rituximab appears across lymphoma, membranous nephropathy, vasculitis, interstitial lung disease, and systemic sclerosis. The studies address efficacy, remission, pharmacokinetics, and adverse events in unrelated settings. Regimens include methotrexate, thiotepa, ibrutinib, and other immunosuppressants. No single therapeutic direction unifies the cluster.

  9 papers · 33.3%

• B-Cell Depletion Across Disorders

  B-cell depletion is examined in leukemia, lupus nephritis, neuromyelitis optica, and systemic disease. Comparisons include vemurafenib, zanubrutinib, cyclophosphamide, mycophenolate, and inebilizumab. Outcomes range from hematologic response to renal function and immunologic change. Several papers are unrelated, so the cluster has no common direction.

  7 papers · 25.9%

• Follicular Lymphoma Therapy

  Relapsed follicular lymphoma care is moving toward combination and immune-directed treatment. Lenalidomide plus rituximab is being tested against rituximab maintenance alone. Epcoritamab combinations are advancing into both relapsed and first-line settings. Progression-free survival, response, relapse, and transformed disease remain central endpoints.

  6 papers · 22.2%

• Multiple Sclerosis B-Cell Therapy

  B-cell therapy in multiple sclerosis is moving toward direct comparison of rituximab and ocrelizumab. Relapse control, disability, pregnancy-related activity, and late-onset neutropenia recur across the clinical studies. Ocrelizumab and rituximab are being evaluated across treatment and reproductive settings. Safety and long-term disease activity remain open questions.

  5 papers · 18.5%